JPWO2021125261A1 - - Google Patents

Info

Publication number
JPWO2021125261A1
JPWO2021125261A1 JP2021565641A JP2021565641A JPWO2021125261A1 JP WO2021125261 A1 JPWO2021125261 A1 JP WO2021125261A1 JP 2021565641 A JP2021565641 A JP 2021565641A JP 2021565641 A JP2021565641 A JP 2021565641A JP WO2021125261 A1 JPWO2021125261 A1 JP WO2021125261A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021565641A
Other languages
Japanese (ja)
Other versions
JP7653712B2 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2021125261A1 publication Critical patent/JPWO2021125261A1/ja
Application granted granted Critical
Publication of JP7653712B2 publication Critical patent/JP7653712B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021565641A 2019-12-18 2020-12-17 高リスク骨髄異形成症候群の治療薬 Active JP7653712B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019228026 2019-12-18
JP2019228026 2019-12-18
PCT/JP2020/047149 WO2021125261A1 (ja) 2019-12-18 2020-12-17 高リスク骨髄異形成症候群の治療薬

Publications (2)

Publication Number Publication Date
JPWO2021125261A1 true JPWO2021125261A1 (enrdf_load_stackoverflow) 2021-06-24
JP7653712B2 JP7653712B2 (ja) 2025-03-31

Family

ID=76477632

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021565641A Active JP7653712B2 (ja) 2019-12-18 2020-12-17 高リスク骨髄異形成症候群の治療薬

Country Status (2)

Country Link
JP (1) JP7653712B2 (enrdf_load_stackoverflow)
WO (1) WO2021125261A1 (enrdf_load_stackoverflow)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040204339A1 (en) * 2001-04-24 2004-10-14 Dimartino Jorge F. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
JP2011520880A (ja) * 2008-05-15 2011-07-21 セルジーン コーポレイション シチジン類似体の経口製剤およびその使用方法
JP2013526525A (ja) * 2010-05-11 2013-06-24 セルジーン コーポレイション レナリドミド及びアザシチジン併用療法による骨髄異形成症候群の治療方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040204339A1 (en) * 2001-04-24 2004-10-14 Dimartino Jorge F. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
JP2011520880A (ja) * 2008-05-15 2011-07-21 セルジーン コーポレイション シチジン類似体の経口製剤およびその使用方法
JP2013526525A (ja) * 2010-05-11 2013-06-24 セルジーン コーポレイション レナリドミド及びアザシチジン併用療法による骨髄異形成症候群の治療方法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BLOOD, THE JOURNAL OF THE AMERICAN SOCIETY OF HEMATOLOGY, vol. 133.10, JPN6024049316, 2019, pages 1086 - 1095, ISSN: 0005480254 *
MIZOROGI F. ET AL.: "Oral administration of cytarabine ocfosfate and 6-mercaptopurine in elderly patients at high risk fo", JIKEIKAI MED. J., vol. 45, no. 3, JPN6021006299, 1998, pages 57 - 66, ISSN: 0005480259 *
PILORGE S. ET AL.: "The autommune manifestations associated with myelodysplastic syndrome respond to 5-azacytidine: a re", BRITISH JOURNAL OF HAEMATOLOGY, vol. 153, no. 5, JPN6021006295, 2011, pages 664 - 665, XP055836224, ISSN: 0005480256, DOI: 10.1111/j.1365-2141.2010.08557.x *
WESNER N. ET AL.: "Inflammatory disorders associated with trisomy 8-myelodysplastic syndromes: French retrospective cas", EUR. J. HAEMATOL., vol. 102, JPN6021006296, 2019, pages 63 - 69, ISSN: 0005480257 *
久松理一: "6-チオプリン/アザチオプリン", 薬局, vol. 67, no. 6, JPN6021006293, 2016, pages 27 - 31, ISSN: 0005480255 *
吉田篤史; 遠藤豊; 上野文昭: "Trisomy8 を伴った骨髄異形成症候群に合併した小腸潰瘍", 日本消化器内視鏡学会雑誌, vol. 57.2, JPN6024035190, 2015, pages 170 - 171, ISSN: 0005480260 *
押見和夫ほか: "MDSにおける化学療法および分化誘導療法", 医学のあゆみ, vol. 158, no. 11, JPN6021006297, 1991, pages 729 - 731, ISSN: 0005480258 *

Also Published As

Publication number Publication date
JP7653712B2 (ja) 2025-03-31
WO2021125261A1 (ja) 2021-06-24

Similar Documents

Publication Publication Date Title
BR112021017339A2 (enrdf_load_stackoverflow)
BR112021018450A2 (enrdf_load_stackoverflow)
BR112021017637A2 (enrdf_load_stackoverflow)
BR112021017939A2 (enrdf_load_stackoverflow)
BR112021017892A2 (enrdf_load_stackoverflow)
BR112021017738A2 (enrdf_load_stackoverflow)
BR112021017782A2 (enrdf_load_stackoverflow)
BR112021016821A2 (enrdf_load_stackoverflow)
BR112021018452A2 (enrdf_load_stackoverflow)
BR112021017728A2 (enrdf_load_stackoverflow)
BR112021017234A2 (enrdf_load_stackoverflow)
BR112021018168A2 (enrdf_load_stackoverflow)
BR112021017703A2 (enrdf_load_stackoverflow)
BR112021017732A2 (enrdf_load_stackoverflow)
BR112021015080A2 (enrdf_load_stackoverflow)
BR112021018250A2 (enrdf_load_stackoverflow)
BR112021017355A2 (enrdf_load_stackoverflow)
BR112021018093A2 (enrdf_load_stackoverflow)
BR112021017173A2 (enrdf_load_stackoverflow)
BR112021018102A2 (enrdf_load_stackoverflow)
BR112021018584A2 (enrdf_load_stackoverflow)
BR112021017310A2 (enrdf_load_stackoverflow)
BR112021016996A2 (enrdf_load_stackoverflow)
BR112021017083A2 (enrdf_load_stackoverflow)
BR112021018484A2 (enrdf_load_stackoverflow)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250311

R150 Certificate of patent or registration of utility model

Ref document number: 7653712

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150